Natural Remedies has been awarded for sustainable practices by CII-ITC Centre of Excellence for Sustainable Development, and for quality by the United States Pharmacopeial Convention.
Photo © iStockphoto.com/adventtr
CII-ITC Centre of Excellence for Sustainable Development, a not-for-profit, industry-led institution that helps businesses become sustainable organizations, awarded Natural Remedies (Bangalore, India) its CII-ITC Sustainability Award in Biodiversity. As part of the company’s sustainability program, reducing pesticide residue and runoff is a high priority. To this end, Natural Remedies conducts pesticide residue and heavy metals analysis beyond the specified limits of soil and water. The firm also trains local farmers on how to best avoid pesticide residues, and works with an NGO to train herb collectors in sustainable collection practices.
In biodiversity impact assessments, Natural Remedies assessed diversion, harvest and percolation surface runoff on ground water, and recharge to borewells in the 90-acre vicinity of the factory site. It also assessed the impact on birds, reptiles and small mammal population in the surrounding region.
In addition to its efforts to practice sustainability, Natural Remedies was recognized by the United States Pharmacopeial Convention with a Platinum Donor Recognition trophy for its participation in USP’s standards-setting activities in 2018. “Natural Remedies contribution adds significant public benefit to the standards-setting process in support of the USP mission which is to improve global health through public standards and related programs that help ensure quality, safety and benefit of medicines and foods,” said Ronald T. Piervincenzi, USP chief executive officer, in a press release.
Natural Remedies’ patented, branded ingredients are clinically substantiated, and the company supplies phytochemical reference standards from Indian medicinal plants, which are used for quality and research purposed globally.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.